ID: ALA187523

Max Phase: Preclinical

Molecular Formula: C26H24N2O6S

Molecular Weight: 492.55

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CC(C)[C@H](NS(=O)(=O)c1ccc(-c2ccc(NC(=O)c3cc4ccccc4o3)cc2)cc1)C(=O)O

Standard InChI:  InChI=1S/C26H24N2O6S/c1-16(2)24(26(30)31)28-35(32,33)21-13-9-18(10-14-21)17-7-11-20(12-8-17)27-25(29)23-15-19-5-3-4-6-22(19)34-23/h3-16,24,28H,1-2H3,(H,27,29)(H,30,31)/t24-/m0/s1

Standard InChI Key:  HJFONKSERLWIGE-DEOSSOPVSA-N

Associated Targets(Human)

Matrix metalloproteinase 7 1073 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matrix metalloproteinase-2 6627 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matrix metalloproteinase 14 1592 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matrix metalloproteinase-1 7046 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matrix metalloproteinase 13 4133 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matrix metalloproteinase 12 1130 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Matrix metalloproteinase 13 45 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serum albumin 6 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 492.55Molecular Weight (Monoisotopic): 492.1355AlogP: 4.74#Rotatable Bonds: 8
Polar Surface Area: 125.71Molecular Species: ACIDHBA: 5HBD: 3
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 3.33CX Basic pKa: CX LogP: 4.56CX LogD: 1.14
Aromatic Rings: 4Heavy Atoms: 35QED Weighted: 0.33Np Likeness Score: -1.07

References

1. Wu J, Rush TS, Hotchandani R, Du X, Geck M, Collins E, Xu ZB, Skotnicki J, Levin JI, Lovering FE..  (2005)  Identification of potent and selective MMP-13 inhibitors.,  15  (18): [PMID:16005220] [10.1016/j.bmcl.2005.06.019]
2. Li J, Rush TS, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, Tam S, Cunningham KM, Chockalingam PS, Morris EA, Levin JI..  (2005)  Synthesis and SAR of highly selective MMP-13 inhibitors.,  15  (22): [PMID:16153831] [10.1016/j.bmcl.2005.08.001]
3. Li W, Li J, Wu Y, Wu J, Hotchandani R, Cunningham K, McFadyen I, Bard J, Morgan P, Schlerman F, Xu X, Tam S, Goldman SJ, Williams C, Sypek J, Mansour TS..  (2009)  A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408).,  52  (7): [PMID:19278250] [10.1021/jm900093d]
4. Li W, Li J, Wu Y, Rancati F, Vallese S, Raveglia L, Wu J, Hotchandani R, Fuller N, Cunningham K, Morgan P, Fish S, Krykbaev R, Xu X, Tam S, Goldman SJ, Abraham W, Williams C, Sypek J, Mansour TS..  (2009)  Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.,  52  (17): [PMID:19725580] [10.1021/jm900809r]
5. Li W, Hu Y, Li J, Thomason JR, DeVincentis D, Du X, Wu J, Hotchandani R, Rush TS, Skotnicki JS, Tam S, Chockalingam PS, Morris EA, Levin JI..  (2009)  3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.,  19  (16): [PMID:19625186] [10.1016/j.bmcl.2009.07.008]

Source